the National Natural Science Foundation for Young Scholars of China(81501736);the Special Research Fund for Doctoral Program of Higher Education(20135503120008)
Min ZHAO, Zhenzhen ZHANG, Quanbo LIU. Effect of miRNA-146a on life cycle of hepatitis B virus in vitro[J]. Journal of Third Military Medical University, 2017, 39(17): 1702-1708.
DOI:
Min ZHAO, Zhenzhen ZHANG, Quanbo LIU. Effect of miRNA-146a on life cycle of hepatitis B virus in vitro[J]. Journal of Third Military Medical University, 2017, 39(17): 1702-1708. DOI: 10.16016/j.1000-5404.201702123.
Effect of miRNA-146a on life cycle of hepatitis B virus in vitro
摘要
目的
2
研究微小RNA-146a(microRNA-146a,miR-146a)对乙型肝炎病毒(hepatitis B virus,HBV)生活周期的影响及其可能机制。
To determine the effect of microRNA-146a (miR-146a) on the life cycle of hepatitis B virus (HBV) and investigate the underlying mechanisms.
Methods
2
The miRNA expression profiles were compared by miRNA array between HepG2 and HepG2.2.15 cells. Then miR-146a was chosen as objective
and its expression level was further confirmed by RT-PCR. After miR-146a mimic and inhibitor were transfected into HepG2.2.15 cells respectively
the quantification of HBV replication was determined by RT-PCR
and the levels of HBsAg and HBeAg in the supernatant were measured by ELISA
and the expression of HS3ST3B1 at mRNA and protein levels were tested by RT-PCR and Western blotting. Dual-luciferase reporter assay was used to detect the interaction between miR-146a and potential target HS3ST3B1.
Results
2
The expression levels of totally 72 miRNAs were changed in HepG2.2.15 cells
with 27 up-regulated and 45 down-regulated. RT-PCR showed the expression level of miR-146a was significantly higher in HepG2.2.15 cells than HepG2 cells (1.55±0.13
vs
1.00±0.01
P
<
0.05). Transfection of miR-146a mimic into HepG2.2.15 cells resulted in significantly increased HBV replication and levels of HBsAg and HBeAg (
P
<
0.05)
while the transfection of its inhibited caused opposite results (
P
<
0.05).Bioinformatic analysis showed that HS3ST3B1 was a potential target of miR-146a. The reporter luciferase reporter system indicated that the reported fluorescence intensity of HS3ST3B1 wild type vector was significantly lower than that of the control group (
P
<
0.05)
but showed no significant difference between HS3ST3B1 mutant vector and control group (
P
>
0.05). The mRNA level of HS3ST3B1 was not significantly changed in HepG2.2.15 cells transfected with miR-146a mimic (
P
>
0.05)
but its protein level was significantly decreased (
P
<
0.05).
Conclusions
2
miR-146a affects the life cycle of HBV
which may be through suppressing the translation of HBV inhibitory factor HS3ST3B1 3′UTR.
关键词
Keywords
references
LAMONTAGNE R J, BAGGA S, BOUCHARD M J. Hepatitis B virus molecular biology and pathogenesis[J]. Hepatoma Res, 2016, 2: 163-186. DOI:10.20517/2394-5079.2016.05.
ZHANG C, ZHONG Y, GUO L. Strategies to prevent hepatitis B virus infection in China: immunization, screening, and standard medical practices[J]. Biosci Trends, 2013, 7(1): 7-12.
HOOFNAGLE J H, LAU D. New therapies for chronic hepatitis B[J]. J Viral Hepat, 1997, 4(Suppl 1): 41-50. DOI:10.1111/liv.13086.
EL-SERAG H B. Epidemiology of viral hepatitis and hepatocellular carcinoma[J]. Gastroenterology, 2012, 142(6): 1264-1273.e1. DOI:10.1053/j.gastro.2011.12.061.
BLUM H E. History and Global Burden of Viral Hepatitis[J]. Dig Dis, 2016, 34(4): 293-302. DOI:10.1159/000444466.
ZOULIM F, DURANTEL D. Antiviral Therapies and Prospects for a Cure of Chronic Hepatitis B[J]. Cold Spring Harb Perspect Med, 2015, 5(4). DOI:10.1101/cshperspect.a021501.
GISH R G, GIVEN B D, LAI C L, et al. Chronic hepatitis B: Virology, natural history, current management and a glimpse at future opportunities[J]. Antiviral Res, 2015, 121: 47-58. DOI:10.1016/j.antiviral.2015.06.008.
LIi L, CHEN X P, LI Y J. MicroRNA-146a and human disease[J]. Scand J Immunol, 2010, 71(4): 227-231. DOI:10.1111/j. 1365-3083.2010.02383.x.
SABA R, SORENSEN D L, BOOTH S A. MicroRNA-146a: a dominant, negative regulator of the innate immune response[J]. Front Immunol, 2014, 5:578. DOI: 10.3389/fimmu.2014.00578.
HAYES C N, CHAYAMA K. MicroRNAs as biomarkers for liver disease and hepatocellular carcinoma[J]. Int J Mol Sci, 2016, 17(3):280. DOI: 10.3390/ijms17030280.
REN J P, YING R S, CHENG Y Q, et al. HCV-induced miR146a controls SOCS1/STAT3 and cytokine expression in monocytes to promote regulatory T-cell development[J]. J Viral Hepat, 2016, 23(10): 755-766. DOI:10.1111/jvh.12537.
RUSCA N, MONTICELLI S. MiR-146a in Immunity and Disease[J]. Mol Biol Int, 2011, 2011: 437301. DOI:10.4061/2011/437301.
ZHAO J L, STARCZYNOWSKI D T. Role of microRNA-146a in normal and malignant hematopoietic stem cell function[J]. Front Genet, 2014, 9; 5:219. DOI: 10.3389/fgene.2014.00219.eCollection 2014.
SELLS M A, ZELENT A Z, SHVARTSMAN M, et al. Replicative intermediates of hepatitis B virus in HepG2 cells thatproduce infectious virions[J]. J Virol, 1988, 62(8): 2836-2844.
ZHANG Z, LIU X, CHEN J, et al. Heparin sulphate D-glucosaminyl 3-O-sulfotransferase 3B1 plays a role in HBV replication[J]. Virology, 2010, 406(2): 280-285. DOI:10. 1016/j.virol.2010.07.030.
HOU Z H, HAN Q J, ZHANG C, et al. miR146a impairs the IFN-induced anti-HBV immune response by downregulating STAT1 in hepatocytes[J]. Liver Int, 2014, 34(1): 58-68. DOI:10.1111/liv.12244.
RIAZALHOSSEINI B, MOHAMED Z, APALASAMY Y D, et al. Association between microRNA-196A2 and microRNA-146A polymorphisms and progression to cirrhosis and hepatocellular carcinoma in patients with viral hepatitis B[J]. Pharmacogenet Genomics, 2016, 26(2): 74-79. DOI:10.1097/FPC.0000000000000187.
GUO L, YANG X, DUAN T. Altered microRNA expression profile in maternal and fetal liver of HBV transgenic mouse model[J]. J Matern Fetal Neonatal Med, 2012, 25(10): 2071-2077. DOI:10.3109/14767058.2012.678431.
WANG S, ZHANG X, JU Y, et al. MicroRNA-146a feedback suppresses T cell immune function by targeting Stat1 in patients with chronic hepatitis B[J]. J Immunol, 2013, 191(1): 293-301. DOI:10.4049/jimmunol.1202100.
HOU Z, ZHANG J, HAN Q, et al. Hepatitis B virus inhibits intrinsic RIG-I and RIG-G immune signaling via inducing miR146a[J]. Sci Rep, 2016, 6:26150.DOI: 10.1038/srep26150.
LINDOW M, KAUPPINEN S. Discovering the first microRNA-targeted drug[J]. J Cell Biol, 2012, 199(3): 407-412. DOI:10.1083/jcb.201208082.
SRSF1 inhibits HBV replication by enhancing the stability of P53 in cell models
Dynamic analysis of serum markers of HBV in 302 infants of pregnant women with HBV infection
Primary identification of compounds targeting hepatitis B virus capsid formation from the FDA approved drugs
Effect of interferons on expression of adenosine deaminase acting on RNA 1 and hepatitis B virus replication in human hepatocellular carcinoma cells in vitro
Roles and mechanisms of long non-coding RNA EHHADH-AS1 in HBV+ hepatocellular carcinoma
Related Author
LIU Jiajun
LONG Shaoyuan
HU Jieli
CUI Jing
Jing WANG
Yan ZHU
Zhongwei LIU
Huimin LIU
Related Institution
Key Laboratory of Molecular Biology for Infectious Diseases of Ministry of Education, Chongqing Medical University
First Affiliated Hospital, Air Force Medical University
Institute of Infectious Diseases, Chongqing Key Laboratory of Infectious Diseases Research, First Affiliated Hospital, Army Medical University (Third Military Medical University)